Illumina, Inc. $ILMN Holdings Lifted by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 90.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,908 shares of the life sciences company’s stock after acquiring an additional 4,708 shares during the period. Chicago Partners Investment Group LLC’s holdings in Illumina were worth $969,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Empowered Funds LLC lifted its position in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in Illumina in the 2nd quarter valued at approximately $621,000. Farther Finance Advisors LLC increased its stake in Illumina by 9.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,521 shares of the life sciences company’s stock valued at $241,000 after buying an additional 225 shares during the period. Park Avenue Securities LLC lifted its position in Illumina by 9.5% in the 2nd quarter. Park Avenue Securities LLC now owns 6,609 shares of the life sciences company’s stock worth $631,000 after buying an additional 571 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Illumina by 199.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,465 shares of the life sciences company’s stock valued at $235,000 after buying an additional 1,642 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

ILMN opened at $150.28 on Friday. The company has a market cap of $22.96 billion, a PE ratio of 33.70, a price-to-earnings-growth ratio of 2.56 and a beta of 1.41. The stock has a 50-day moving average of $135.20 and a 200-day moving average of $113.14. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm’s revenue was up .4% compared to the same quarter last year. During the same period last year, the business earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ILMN. Barclays upped their price target on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. TD Cowen restated a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. JPMorgan Chase & Co. upped their target price on Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Evercore ISI reaffirmed an “outperform” rating and set a $155.00 price target on shares of Illumina in a research note on Monday, January 5th. Finally, UBS Group lifted their price target on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $124.47.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 500 shares of Illumina stock in a transaction dated Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is currently owned by insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.